New apalutamide study opens for prostate cancer

February 14, 2018

A new phase 3 study at Providence Cancer Institute will compare the effectiveness of three different treatment regimens in men with biochemically recurrent prostate cancer:

Experimental arm: apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor, plus degarelix, a hormonal therapy used to reduce testosterone
Experimental arm: apalutamide and degarelix plus abiraterone acetate and prednisone
Control arm: degarelix alone

“Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer,” according to findings from the phase 3 SPARTAN trial reported in OncLive on Feb. 5. The SPARTAN trial, published in the New England Journal of Medicine on Feb. 8, found that “median metastasis-free survival was more than 2 years longer” for men who received apalutamide. Read more in the New York Times.

Brendan Curti, M.D., the principal investigator of the new three-arm study at Providence Cancer Institute, is a medical oncologist and director of genitourinary oncology research at the Earle A. Chiles Research Institute.

See Providence study details here:

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

More prostate cancer studies

This study is one of three clinical trials open to men with prostate cancer at Providence Cancer Institute. See all prostate cancer studies.

To refer patients to any of these studies, call Providence Cancer Institute’s Clinical Research office at 503-215-2614 or visit oregon.providence.org/clinical-trials.

Welcome to your journey for creating a healthier you

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

New apalutamide study opens for prostate cancer

See Providence study details here:

More prostate cancer studies

Previous Article

Next Article

Most Recent Articles

Providence Cancer Institute is the first facility in the Pacific Northwest, and the first community medical center in the country, to offer MRI-guided radiation therapy for patients with pancreatic ca

Ingga Smith describes her life before and after having bariatric surgery at the Providence Little Company of Mary Bariatric Wellness Center.

David March was admitted to St. Jude Medical Center with coronavirus on April 1. The next day, he was put on a ventilator in an induced coma where he would remain for 17 days. With his chances for

Donations toward St. Jude’s Emergency Response & Recovery Campaign are helping provide immediate relief and support to front line caregivers. In addition to food and supplies gifted by the community

Funds from St. Jude’s Emergency Response & Recovery Campaign are helping equip and expand the hospital’s Caring Neighbors Program — an initiative that assists frail and isolated seniors with services

Donations toward St. Jude’s Neighbors Helping Neighbors Emergency Response & Recovery Campaign enabled the purchase of 60 high-efficiency particulate air (HEPA) filters, which are being used to clean

Providence Sacred Heart Medical Center & Children’s Hospital has been recognized as a Best Hospital in the region. Providence Holy Family Hospital recognized as high performing in knee replacement.

Providence Cancer Institute now offers cancer patients the most cutting-edge radiation technology in the world.

Our youth volunteers have given hundreds of hours of their time to Providence Holy Cross and during the COVID-19 pandemic many have been showing their appreciation with handmade thank you cards and tr

Pushing the boundaries of innovation in minimally invasive surgeries, St. Mary Medical Center recently implemented the only da Vinci Xi Surgical System in the High Desert.

Mission Hospital has been awarded an ‘A’ patient safety rating from The Leapfrog Group.

An unmet clinical need exists for patients with cancers associated with human papillomavirus. A new phase I study at Providence Cancer Institute will evaluate a novel biologic therapy in patients with